Table 3.

All-cause Mortality Through Week 48 Post–hematopoietic Cell Transplant Among Patients Who Developed Clinically Significant Cytomegalovirus Infection (Full Analysis Set)

	Letermovir (n = 325)			Placebo (n = 170)
	n/N (%)	HRa (95% CI)	P Value	n/N (%)	HRa (95% CI)	P Value
CS-CMVi (time dependent)	9/57 (15.8)	1.15 (0.56–2.37)	.71	22/71 (31.0)	2.34 (1.17–4.67)	.02
No CS-CMVi (time dependent)	52/268 (19.4)	…		18/99 (18.2)	…

Graft-versus-host disease and baseline risk of CMV reactivation were not adjusted for in the model due to multicollinearity (both variables were highly correlated with CS-CMVi). CS-CMVi is treated as a time-dependent variable in the model because the time of onset of CS-CMVi varies for each subject. Death includes all-cause mortality through week 48 post-HCT. Clinically significant CMV infection is defined through week 24 post-HCT. Denominator in the first row only includes subjects with clinically significant CMV infection and does not include subjects who discontinued early and had missing data. Every subject is counted a single time for each applicable row and column.

Abbreviations: CI, confidence interval; CMV, cytomegalovirus; CS-CMVi, clinically significant cytomegalovirus infection; HCT, hematopoietic cell transplantation; HR, hazard ratio.

^aHR is adjusted for baseline age.